Ruxolitinib phosphate

Physical and Chemical Properties Approval for Use Side Effects

Product Name: Ruxolitinib phosphate
CAS No.: 1092939-17-7
Chemical Name: Ruxolitinib phosphate
Synonyms: INC424;INCB 018424;INC 424 phosphate;Ruxotinib phosphate;Jakafi (ruxolitinib);IINCB018424 phosphate;Ruxolitinib, Phosphate;INCB018424 (phosphate);10-dimethoxyptercarpan;INCB 018424 (phosphate)
CBNumber: CB82509943
Molecular Formula: C17H21N6O4P
Formula Weight: 404.37
MOL File: 1092939-17-7.mol

More

Less

Ruxolitinib phosphate Property

Melting point:: 186-190°C
storage temp.: Refrigerator
solubility: DMSO (Slightly), Methanol (Slightly)
form: Solid
color: White to Off-White

More

Less

Safety

HS Code: 29331990

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

H361Suspected of damaging fertility or the unborn child

H373May cause damage to organs through prolonged or repeated exposure

Precautionary statements

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

More

Less

N-Bromosuccinimide Price

Cayman Chemical

Product number: 23215
Product name: Ruxolitinib (phosphate)
Purity: ≥98%
Packaging: 1mg
Price: $32
Updated: 2024/03/01

Cayman Chemical

Product number: 23215
Product name: Ruxolitinib (phosphate)
Purity: ≥98%
Packaging: 5mg
Price: $116
Updated: 2024/03/01

Cayman Chemical

Product number: 23215
Product name: Ruxolitinib (phosphate)
Purity: ≥98%
Packaging: 10mg
Price: $199
Updated: 2024/03/01

Cayman Chemical

Product number: 23215
Product name: Ruxolitinib (phosphate)
Purity: ≥98%
Packaging: 25mg
Price: $381
Updated: 2024/03/01

Tocris

Product number: 7048
Product name: Ruxolitinibphosphate
Purity: ≥98%(HPLC)
Packaging: 50
Price: $229
Updated: 2021/12/16

More

Less

Ruxolitinib phosphate Chemical Properties,Usage,Production

Physical and Chemical Properties

Ruxolitinib, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3- cyclopentylpropanenitrile phosphate, has a molecular weight of 404.36 kDa. Ruxolitinib is soluble in aqueous solutions at pH 1-8. Ruxolitinib tablets are stable at 20-25°C and tolerate brief exposures to temperatures outside this range, if they stay within 15-30°C.

Approval for Use

Ruxolitinib is an oral inhibitor of JAK1 and JAK2, which is approved for the treatment of myeloproliferative neoplasm-associated myelofibrosis, further myeloproliferative neoplasms, polycythemia vera and refractory cancer. In the USA, Canada and EU, ruxolitinib is approved for the treatment of patients with intermediate or high-risk PMF, post-PV MF or post-ET MF. In addition, ruxolitinib recently has been approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea, based on the results of Phase II and III clinical studies. To date, ruxolitinib has been approved for indications in MF in 83 countries.

Side Effects

Common side effects of ruxolitinib treatment include anaemia and thrombocytopenia. The decline of circulating erythrocytes following ruxolitinib treatment could result in part from stimulation of eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the cell surface. Cellular mechanisms involved in the execution of eryptosis include oxidative stress, Ca2+ entry with increase of cytosolic Ca2+ activity ([Ca2+]i), ceramide, decline of cytosolic ATP, caspases, stimulated activity of casein kinase 1α, Janus-activated kinase JAK3, protein kinase C, and p38 kinase, as well as impaired activity of AMP activated kinase AMPK, cGMP-dependent protein kinase, PAK2 kinase and sorafenib/sunitinib sensitive kinases.

Uses

The phosphate salt of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.

Definition

ChEBI: A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essent al thrombocythemia myelofibrosis.

Clinical Use

Ruxolitinib phosphate is a potent, selective, ATP competitive inhibitor of tyrosine-protein kinases JAK1 and JAK2 which acts by attenuating cytokine signaling and promotes apoptosis. Ruxolitinib was discovered and developed by Incyte, is marketed under the brand name Jakafi,and is approved for the treatment of patients with myelofibrosis (MF), including primary MF, post-polycythemia vera MP, and post-essential thrombocythemia MF. Ruxolitinib is also undergoing clinical evaluation against a wide variety of cancer indications including metastatic prostate cancer, pancreatic cancer, multiple myeloma, leukemia, non-Hodgkin lymphoma, and breast cancer. Additionally, ruxolitinib is being evaluated for the treatment of psoriasis and thrombocytopenia.

Synthesis

Ruxolitinib contains one chiral center, and three general strategies for its preparation have been reported.165¨C167 These include a racemic synthesis followed by chiral separation or resolution, introduction of the side chain via an aza-Michael addition of the pyrazole fragment to 3- cyclopentylpropiolonitrile and asymmetric hydrogenation of the resulting alkene, and through introduction of the side chain via an organocatalytic, asymmetric aza-Michael addition. The route described herein utilizes the first strategy as this appears to be the largest scale reported.
The synthesis was initiated by SEM protection of commercially available chloropyrrolopyrimidine 201 to provide the protected chloropyrrolopyrimidine 202 in 89% yield. Suzuki coupling of 202 with the pyrazole pinacolatoboronate 203 gave pyrazole 204 in 64% yield. aza-Michael reaction of pyrazole 204 with 3-cyclopentylacrylonitrile 205 was accomplished in the presence of DBU to furnish SEM-protected ruxolitinib 206 in 98% yield as the racemate. The desired enantiomer 207 was isolated via chiral column separation in 93.5% yield and 99.4% ee, on 100 kg scale. Removal of the SEM group was accomplished through a two step process via treatment with lithium tetrafluoroborate and aqueous ammonium hydroxide, ultimately giving rise to ruxolitinib 208 in 84% yield. The phosphate salt was then prepared by treatment with phosphoric acid. Crystallization from MeOH/i-PrOH/n-heptane gave ruxolitinib phosphate (XX) in good overall yield in 99.8% ee. Pyrazole pinacolatoboronate 203 was prepared from pyrazole 209 via iodination with N-iodosuccinimide followed by reaction with trimethyl silyl chloride to give protected iodopyrazaole 210 in high yield. Reaction of 210 with i-PrMgCl to form the corresponding Grignard reagent followed by reaction with isopropylpinacolborane 211 provided Suzuki boronate synthon 203 in 55% yield.

storage

Store at -20°C

Ruxolitinib phosphate Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Ruxolitinib phosphate Suppliers

Canada 1 China 264 India 10 United Kingdom 2 United States 19 Global 296

Jiaxing Zhonghui Biotechnology Co. Ltd

Tel: 17324007174
Email: jiangfeng2016@126.com
Country: China
ProdList: 57
Advantage: 55

Changzhou Yongfeng Biomedicine Co. Ltd.

Tel: 15006117673
Fax: 2973592490@.com
Email: 2973592490@qq.com
Country: China
ProdList: 311
Advantage: 58

Nanjing zehe Pharmaceutical Technology Co., Ltd

Tel: 17768115366
Email: henry124604479@163.com
Country: China
ProdList: 289
Advantage: 58

Bayee Biotech (Anqing) Co., Ltd.

Tel: 0556-5032306 18917961636
Fax: +86-556-5032307
Email: wtx@bayeebio.com
Country: China
ProdList: 253
Advantage: 61

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Tel: 0311-67591193 15030197620
Fax: QQ:2786999724
Email: sales02@dingminpharma.com
Country: China
ProdList: 299
Advantage: 58

Sichuan Qingmu Pharmaceutical Co., Ltd.

Tel: +86-28-87827187 +86-15258599553
Email: sales@eastonpharma.cn
Country: China
ProdList: 76
Advantage: 60

HANGZHOU YOUHELIN PHARMTECH CO.LTD

Tel: 18268150871; 17302275155
Email: tanglulu11129@163.com
Country: China
ProdList: 28
Advantage: 58

TargetMol Chemicals Inc.

Tel: 021-33632979 15002134094
Fax: 021-33632979
Email: marketing@targetmol.com
Country: China
ProdList: 7934
Advantage: 58

Taizhou Yuxin Biotechnology Co., Ltd.,

Tel: +86-0576--88902229 +86-13968687450
Email: yuxin@yuxchem.com
Country: China
ProdList: 155
Advantage: 58

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2923
Advantage: 55

More

Less

View Lastest Price from Ruxolitinib phosphate manufacturers

Henan Fengda Chemical Co., Ltd

Product: Ruxolitinib phosphate 1092939-17-7
Price: US $8.00-0.80/KG
Min. Order: 1KG
Purity: 99%
Supply Ability: g-kg-tons, free sample is available
Release date: 2024-04-09

Nanjing Fred Technology Co., Ltd

Product: Ruxolitinib Phosphate 1092939-17-7
Price: US $0.00-0.00/kg
Min. Order: 1kg
Purity: 99%, Single impurity＜0.1
Supply Ability: 1 ton
Release date: 2023-12-20

Shanghai Qianyi New Material Co., Ltd.

Product: Ruxolitinib phosphate 1092939-17-7
Price: US $300.00-160.00/kg
Min. Order: 9000kg
Purity: 99%
Supply Ability: 10kg
Release date: 2023-04-19

1092939-17-7, Ruxolitinib phosphateRelated Search:

Ruxolitinib S-Ruxolitinib (INCB018424) 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Rucaparib LIMAPROST Linagliptin PF-01367338 LOXO-101 Lapatinib Erlotinib Cabozantinib Sunitinib Lenvatinib BKM120 (NVP-BKM120, Buparlisib) Niraparib tosylate MK-4827 (tosylate) Epacadostat (INCB024360) Alectinib Hydrochloride

(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate

INCB 018424

Ruxolitinib, Phosphate Salt

Ruxolitinib, Phosphate

(βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazole-1-propanenitrile Phosphate

INCB018424;INCB-018424;INCB 018424

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid

Ruxolitinib (INCB-18424) phosphate

Jakafi (ruxolitinib)

Ruxolitinib phosphate, >=98%

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

RUXOLITINIB(INCB018424) PHOSPHATE

Ruxotinib phosphate

Ruxolitinib phosphate(INCB018424)

Beta-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(Betar)-1H-pyrazole-1-propanenitrile, phosphate

(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosph

INCB 018424(Ruxolitinib Phosphate)

INCB 018424 (phosphate)

INCB018424 (phosphate)

INCB-018424 (phosphate)

(R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate

INCB018424 PHOSPHATE;INCB 018424 PHOSPHATE;INCB-018424 PHOSPHATE;RUXOLITINIB

RUXOLITINIB PHOSPHATE (INCB018424 PHOSPHATE)

INC 424 phosphate

INC424

Ruxolitinib phosphate ISO 9001：2015 REACH

Ruxolitinib Phosphate (INC-424, INCB-18424, INCB-018424, Jakafi and Jakavi)

phosphenoperoxoic acid compound with (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile and dihydrogen (1:1:1)

(3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate

10-dimethoxyptercarpan

IINCB018424 phosphate

(βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate

1092939-17-7

C17H18N6H3PO4

C17H21N6O4P

Intracellular signaling.

Inhibitors

Antineoplastic

API